

Date: October 13, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Outcome of Board Meeting of the Company held on Tuesday, October 13, 2026

With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, has inter-alia, approved the following:

1. Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the re-appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company, liable to retire by rotation for a period of three (3) consecutive years w.e.f. October 15, 2026 subject to the approval of shareholders to be obtained through postal ballot process.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure- A**.

2. Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the re-appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company, liable to retire by rotation for a period of three (3) consecutive years w.e.f. November 10, 2026 subject to the approval of shareholders to be obtained through postal ballot process.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure- B**.

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Kindly note that the meeting of Board of Directors of the Company commenced at 11:30 AM (IST) and concluded at 11:55 PM (IST):.

This intimation and aforesaid information are also being uploaded on the Company's website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

SHILPA
SHARMA

Digitally signed by SHILPA
SHARMA
DN: cn=SHILPA SHARMA, c=IN,
o=Personal,
email=csshilpa.agarwal@gmail.com
Date: 2026.10.13 12:15:10 +05'30'

Shilpa Sharma

Company Secretary & Compliance Officer
ICSI Membership No.: A34516

Enclosures: As above

Committed to
Global Wellness!

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-Appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Managing Director of the Company.
2.	Date of appointment/re-appointment/cessation (as applicable) and-term of appointment	For a further period of three (3) consecutive years w.e.f. October 15, 2026 subject to the approval of shareholders to be obtained through postal ballot process.
3.	Brief Profile (in case of re-appointment)	Mr. Swapnil Jatinbhai Shah is the Promoter and Managing Director of the Company. He has over 15 years of experience in the pharmaceutical sector. He was previously involved in business operations in a Delaware based pharmaceutical company. He is currently leading the Company's overall functioning and is a part of the core management team. He is also responsible for product portfolio management, corporate strategy, business development and overall strategic management of our Company. He holds a master's degree in business administration from Hofstra University, New York and a bachelor's degree in chemical engineering from Nirma University. He was previously associated as a strategist at Planet Payment Inc. (now acquired by Fintx, Inc., a fintech company listed on the NASDAQ). He is a convenor of the pharma panel in the Confederation of Indian Industry (CII), Gujarat State Council.
4.	Disclosure of relationships between directors (in case of re-appointment of a director)	Mr. Swapnil Jatinbhai Shah is not related inter-se to any other Directors of Company.
5.	Information as required under BSE circular no. LIST/COMP/14/2018- 19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	Mr. Swapnil Jatinbhai Shah is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Senores Pharmaceuticals Limited

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: info@senorespharma.com

 W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole Time Director of the Company

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-Appointment of Mr. Chetan Bipinchandra Shah (DIN: 10381971) as the Whole-time Director of the Company.
2.	Date of appointment/re-appointment/cessation (as applicable) and-term of re-appointment	For a further period of three (3) consecutive years w.e.f. November 10, 2026 subject to the approval of shareholders to be obtained through postal ballot process.
3.	Brief Profile (in case of re-appointment)	Mr. Chetan Bipinchandra Shah is the Whole-Time Director and Chief Operating Officer of the Company. He has over 30 years of experience of which 25 years of experience is in the pharmaceutical industry and was previously associated with pharmaceutical companies such as Torrent Pharmaceuticals Limited and Cadila Pharmaceuticals Limited. He was also associated with Reliance Retail Limited, Reliance Fresh Limited and Reliance Corporate IT Park Limited. He is a part of the core management team of the Company and is responsible for strategy planning, capital expenditure planning, capacity expansion, policy enforcement, mergers and acquisitions, supply chain for both domestic and international chain, manufacturing processes and automation, risk management and overall management information system.
4.	Disclosure of relationships between directors (in case of re-appointment of a director)	Mr. Chetan Bipinchandra Shah is not related inter-se to any other Directors of Company.
5.	Information as required under BSE circular no. LIST/COMP/14/2018- 19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	Mr. Chetan Bipinchandra Shah is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Senores Pharmaceuticals Limited

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: info@senorespharma.com

 W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263